Esperion Logo (primary).png
Esperion Reports First Quarter 2022 Financial Results and Provides Company Update
May 03, 2022 07:00 ET | Esperion Therapeutics, Inc.
– Unprecedented CLEAR Outcomes Study Approaching 95% MACE Accumulation– – U.S. Net Product Revenue of NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets Grew...
Esperion Logo (primary).png
Esperion Announces Publication of CLEAR Harmony Open-Label Extension Study Data for Bempedoic Acid in the American Journal of Cardiology
May 02, 2022 08:00 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 02, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the publication of data from the CLEAR Harmony Open-Label Extension (OLE) Study of bempedoic acid, also...
Esperion Logo (primary).png
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
April 29, 2022 17:00 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., April 29, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on April 28, 2022, the Compensation Committee of Esperion’s Board of Directors granted 14 new...
Esperion Logo (primary).png
Esperion to Participate in Upcoming Bank of America Securities 2022 Healthcare Conference
April 29, 2022 10:00 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., April 29, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that President and Chief Executive Officer, Sheldon Koenig, will present at the upcoming Bank of America...
Esperion Logo (primary).png
Esperion Announces the Appointment of Stephen Rocamboli to its Board of Directors
April 28, 2022 16:00 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., April 28, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Stephen Rocamboli as a Class I director, with a term expiring at the 2023 annual...
Esperion Logo (primary).png
Esperion Supports Collaborative Study with an Integrated and Learning Health Care Delivery System in Northern California to Study the Effects of NEXLIZET® (bempedoic acid and ezetimibe) in Reducing LDL-Cholesterol Following a Recent Acute Coronary Syndrome Event
April 25, 2022 08:00 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., April 25, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced support for a study to evaluate the effects of bempedoic acid and ezetimibe (NEXLIZET) on short-term...
Esperion Logo (primary).png
Esperion to Report First Quarter 2022 Financial Results May 3, 2022
April 19, 2022 07:00 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., April 19, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report first quarter 2022 financial results before the open of the U.S. financial markets on...
Esperion Logo (primary).png
Esperion Announces Publication of Phase 3 Data for Bempedoic Acid in the Journal of Clinical Lipidology
April 13, 2022 08:00 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., April 13, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the publication of data from a pooled analysis of patients enrolled in four Phase 3 bempedoic acid...
Esperion Logo (primary).png
Esperion Announces Two NEXLETOL® (bempedoic acid) Data Presentations at the American College of Cardiology’s 71st Annual Scientific Session & Expo
April 03, 2022 12:00 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., April 03, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today presented two new analyses from its clinical development program of bempedoic acid (NEXLETOL®) at the American...
Esperion Logo (primary).png
Esperion to Participate in Upcoming 21st Annual Needham Virtual Healthcare Conference
March 29, 2022 08:00 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., March 29, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that President and Chief Executive Officer, Sheldon Koenig, will present at the upcoming Needham 21st...